An ideal infectious disease test is accurate, fast, cheap, and can be performed at home. Read more at Biocompare Future Lab.

The NCI and the NIBIB chose the seven projects from nearly 200 different ideas. The projects represent a broad range of solutions for immediate public health needs related to the pandemic, and several focus on solutions for medically underserved communities and people with limited access to healthcare. Read more Health IT Analytics.

NIH has awarded seven contracts to companies and academic institutions to develop digital health solutions that help address the COVID-19 pandemic.

NIH announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of RADx. These tests add to initial awards made to seven companies on July 31, 2020.

The winners of National Institutes of Health’s 9th annual Design by Biomedical Undergraduate Teams (DEBUT) challenge developed simple and low-cost diagnostics and treatments for conditions such as tuberculosis, cervical cancer, birth defects, and onchocerciasis (river blindness).

NIH announced that AI technology is underway to aid physicians across the United States in the global war against COVID-19. These efforts are taking place with the Medical Imaging and Data Resource Center, which is comprised of research from physicists, physicians, radiologists, and scientists across the country. Read more at The Burgundy Zine.

NIBIB-funded researchers have created nanoparticles for successful gene therapy of a mouse model of macular degeneration. The nanoparticle carriers have the potential to significantly expand the effectiveness of gene therapies for human eye diseases, including blindness.

NIBIB mourns the passing of molecular imaging pioneer and NIBIB Advisory Council member, Sanjiv “Sam” Gambhir, M.D., Ph.D.

The NIH’s Rapid Acceleration of Diagnostics (RADx) initiative seeks to speed up the development of tests. In April, Congress allocated $1.5 billion towards the program; last week, RADx announced the seven tests that passed the preliminary round of vetting and will now be produced en masse. Read more at Quartz
.